Information Makes Good Medicine
by Tom Andel, chief editor
In the march toward material handling excellence, the
pharmaceutical industry has been comfortable following the lead of other
industries. Now it’s ready to set the pace.
Catalysts are big
in the pharmaceutical industry. In formulations, a catalyst causes or
accelerates a chemical change. Manufacturers in the pharmaceutical industry are
becoming masters of change — in manufacturing and distribution — as
they adopt material handling logistics technologies to help them prepare for
their future.
This change is the
result of several catalysts:
• FDA
regulation of the pharmaceutical information supply chain;
• A growing
population of aging customers with prescriptions to fill;
• New drug
formulations requiring specialized handling;
• Plants and
distribution centers that need help anticipating and meeting these demands.
Technology can help
pharmaceutical manufacturers and distributors deal with these challenges, and
the Food and Drug Administration (FDA) knows it. That’s why it issued
guidelines it expects the industry to use as manufacturers implement such tools
as automatic data collection and warehouse management systems (WMS) to track
and trace shipments.
That’s the
purpose of FDA 21 CFR Part 11 of the Code of Federal Regulations. It defines
how companies are to use electronic records and signatures in the production
and/or distribution of FDA-regulated products. It is designed to ensure the
integrity of system operations and information stored in a system. Such
measures encompass:
• Validation;
• The ability
to generate accurate and complete copies of records;
• Use of
computer-generated, time-stamped audit trails;
• Use of
appropriate controls over systems documentation;
• Archival
protection of records;
• A
determination that persons who develop, maintain or use electronic records and
signature systems have the education, training and experience to perform their
assigned tasks.
These capabilities
are crucial to any supply chain that supports public health and welfare. If
you’re part of that chain, you share responsibility for adherence to CFR
Part 11.
“The bar is
being raised so groups that were not part of the regulated supply chain now
are, or soon will be — including the carriers and third-party logistics
[3PLs] providers being employed,” says Todd Applebaum, a researcher and
consultant who works with leading biopharmaceutical companies. “For
example, these players are actually qualifying specific containers that would always
be used to transport their material. What’s becoming more important than
tracking the trailers themselves is the event management — when it
arrives, when it leaves and when it enters customs. Also important is the
monitoring of conditions within the trailer. We’re seeing more active
automated monitoring of those conditions within the trailer, then audits to
make sure the specs are being met.”
Accountability
The early
beneficiaries of adherence to CFR Part 11 will be the quick-moving 3PLs and
other companies that can get an infrastructure in place to provide this across
different industries, not just pharmaceutical, Applebaum adds. These include
industries where critically important products need to be tracked and
monitored, like high-value capital spares, components and products with short
life cycles. In these cases, you not only need to manage the amount of
inventory in the supply chain, but match it to demand.
Pharmaceutical
companies are getting involved in rigorous full-life-cycle supply chain
planning. This happens while drugs are in development and entails distribution
network planning, make vs. buy decisions, planning for future line extensions,
and early trending of demand through demand modeling.
“Everyone is
trying to maintain inventory levels at a very low point while still satisfying
their needs,” says Kevin O’Brien, manager of the Branchburg, New
Jersey, distribution center for Schering-Plough Healthcare Products. “The
Rx industry has never been held to the same standards, but now, more than ever,
we are expected to understand what our customers want. That’s why the
industry is investing in more automated picking and batch control and
coordinating delivery dates.”
Schering
Laboratories, a division of the $9.8 billion Schering-Plough Corp., recently completed
the third installation of Ann Arbor Computer’s mid-range WMS, pcAIM, at
its western region distribution center in Reno, Nevada. The first two
installations were in Branchburg and in its Suwanee, Georgia, facility. The WMS
manages the incoming storage and outgoing distribution of prescription drug
products and samples throughout the United States from these three DCs.
“We can now
trace by lot down to the line-item order level, and our accuracy is near 100
percent,” O’Brien says. “We also ship samples. Within the
WMS, because of requirements by the FDA, sample accountability tracks the
history of a batch or product or a representative distribution.”
He adds that with
biotech becoming more prevalent in his industry, handling requirements will
start to change. New requirements include controlled room shipping, whether
that involves cold product or formulations that must be maintained at a
particular ambient temperature.
“Our future
is contingent on the new products created and generated by our R&D,”
O’Brien concludes. “Our DCs were built with the ability to provide
for future growth.”
Multi-purpose information
The beauty of
logistics data collection technology is that once data are captured, the
information can be used by the enterprise in a wide variety of ways. As data
requirements proliferate, WMS packages are evolving to meet them.
“Originally
pcAIM did lot control and shelf life expiration date tracking only, but
we’ve extended the quality control [QC] part to meet many of this
industry’s requirements,” says Ann Arbor Computer’s Art
Fleischer. “That includes being able to check if a QC status has changed,
even after the product has been picked and before it has gone out the door.
Pharma companies have a lot of archival needs. For recalls, companies must pull
information from archived records. The easiest way to do that is through the
execution layer, which includes the WMS.”
It also includes
automatic data capture; according to Karen Longe, president of Karen Longe
& Associates and a consultant to the pharma industry, this technology
offers significant untapped potential. The FDA’s data management
requirements will bring those benefits to everyone in the supply chain, she
believes.
“The product
side of the healthcare industry has been slow to bar code,” she adds.
“They need bar codes down to the unit-of-issue or dose. And to be really
helpful, you need lot and expiration dates on those doses. That becomes a
challenge, but if you collect information for that reason you can use it for
many other purposes. In addition to patient safety, there are tremendous
benefits to the manufacturer and to everyone else in the supply chain.”
More than just savings
Security has risen
to the top of that list of benefits.
“Security
issues have become an everyday concern at many points in the supply
chain,” agrees Tan Miller, director of distribution planning for Pfizer
Pharmaceuticals. “Within the four walls of the warehouse, individual
products may require special storage and handling procedures simply because of
their high value. That applies over the road, as well. In fact, the attention
to maintaining the integrity and security of the product in transit leads
pharmaceutical manufacturers to employ material handling techniques that one
might not think to use in other industries.”
He cites the use of
overpack cardboard containers to ship pharmaceutical cases. This requires loading pharmaceutical
cases into an overpack container (perhaps at the staging dock) after the
individual cases have already been picked in the warehouse.
“This step
clearly adds a cost at the warehouse loading and shipping stage,” Miller
admits. “On the other hand, this approach can significantly reduce
shortages and the vulnerability to individual cases being stolen in transit. So
the extra cost incurred at the warehouse loading and shipping stage may be more
than offset by the savings in shortages and theft that occur further down the
supply chain. This approach clearly does not make sense for all industries, but
it may have merit for those that use a total supply chain cost
perspective.”
Indeed, with the
high-value product it handles, the pharmaceutical industry in the U.S. and in
Western Europe doesn’t invest in material handling technology to save
costs. The primary goal is to ensure product quality. It’s a different
story in developing countries such as those in Asia or Eastern Europe. In
addition to the economic efficiencies of automation, companies in Poland,
Slovenia and Serbia want a piece of the American market. Automation is the
price of entry.
“Up to now,
these companies produced medications for their home markets and for other
Eastern European markets,” explains Urs Dietler, manager of the Industry
Practice Group, Pharma, at Swisslog, supply chain solutions providers.
“Now they recognize that they can earn more money if they sell to Western
Europe and to the U.S., where medicine prices are much higher. But there is one
condition they have to fulfill: They must produce in accordance with FDA
regulations, and this is almost impossible without automated material handling
processes because their staffs are not sufficiently educated.”
Preparing for growth
As the elder
population grows in the U.S., the demand for new and established
pharmaceuticals will increase. The pharma industry is gearing up for this, but
manufacturers have some difficult choices ahead: either build new DCs, increase
throughput capacity, use third parties, or figure out how to put more
automation to work.
“Areas where
they need to further automate include the replenishment of pick-to-light
systems or automatic dispensing systems,” concludes Jeff Hedges, director
of market development for HK Systems. “When you’re dealing with
high-value, pocket-size components, pilferage is easier. Furthermore,
you’re dealing with high turnover rates within the picking staff. Then,
if you expect throughput to double, do you double the number of pickers,
require them to work faster or add three shifts a day?”
Wyeth
Pharmaceuticals employs 240 people in its Knoxville, Tennessee, distribution
center — one of three U.S. DCs. This one handles 85 percent of the
company’s prescription medications. According to Patrick Flanagan, DC
director, cross-training is key to maintaining a reliable workforce in the
world of pharmaceutical distribution.
“Some come in
at 6 a.m. to begin receiving; others come in at 8:30 to begin picking, and some
come in at 2 to finish picking and shipping, and then they work in
replenishment. Our objective is to ship every order the same day. We are also
set up for emergencies. We have people who are trained and on call 24 hours a
day, seven days a week, to ship lifesaving drugs. It’s not unusual for
someone to be called in on the weekend.”
Technology plays an
important role in eliminating mistakes in this life-or-death occupation. In
fact, the entire 600,000-square-foot facility was designed to house
mistake-proof operations.
“When we
designed this facility we made sure our building control systems, which
maintain the temperature, the electronic security systems, our warehouse
management system and related systems, were all completely validated in
accordance with FDA regulations,” he explains. “We also do
extensive testing and tracking to ensure the packaging we use is
sufficient.”
Wyeth’s
Knoxville DC handles about 500 SKUs, but its capabilities will really be put to
the test as the biotech products currently in R&D reach production.
Facility flow is governed by a WMS from DCS, now known as Vertex Interactive.
Operations are paperless, employing a mix of bar code and RF technologies,
two-and-a-half miles of conveyor, high-speed sorters, and pick-to-light and
pick-to-belt systems.
“The WMS will
accommodate the special handling requirements of our biotech products,”
Flanagan explains. “Storage classes are built in, including refrigerated,
freezer and controlled drugs, so we’ll see more of a physical change than
a systems change. Physically you must make sure you have sufficient
refrigerated space; you make sure it’s validated and that you have the
right technology in place to monitor temperatures. Our building management
system measures temperature in the warehouse and in the refrigerator/freezer
every hour in several stocking positions, and we have alarms that go off if
temperatures go out of tolerance.”
Why did they select
Vertex?
“It had
proven technology in the pharmaceutical industry and its pick-to-light system
enables us to verify the lot number. We could have just bought its
pick-to-light system and someone else’s WMS, but I put in several WMS
packages before, and interfacing one vendor’s technology to
another’s is a major challenge. This package also had an integrated
manifesting system, and the vendor had experience with our conveyor integrator,
Conveyco. The conveyor supplier was Buschman.”
Since Wyeth put these
technologies to work in its Knoxville facility in 1999, shipping accuracy has
reached near 100 percent. “It’s all part of our chairman’s
effort to promote quality,” Flanagan concludes. “Back in March of
this year the company changed its name to Wyeth from American Home Products. We
have taken many such strides in the last few years because we have a busy
pipeline of products and we wanted to make sure
we are in 100
percent regulatory compliance.”
Other leading
players in the pharmaceutical industry are making similarly bold business
moves. Manufacturers are buying up wholesalers. Joint ventures are making
supply chains global. And many facilities are closing as companies update,
improve and streamline their handling and verification processes.
Throughout these
changes, material handling logistics technology will continue to play a key
role in ensuring that healthy supply chains keep their customers healthy as
well. MHM
Pharma Automation in Europe
When it comes to
material handling in the pharmaceutical industry, Europe has long employed a
higher level of automation technology than the U.S. Much of this can be
attributed to cultural and labor cost differences, but historical differences
among distribution channels also play a part.